Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital
Open Access
- 1 September 2010
- journal article
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 92 (6) , 489-494
Abstract
INTRODUCTION We describe our experience with oncology patients on a frequent dosing schedule of intravenous (i.v.) bisphosphonates at the Jordan University Hospital (JUH). PATIENTS AND METHODS Patients treated by i.v. bisphosphonates in the medical oncology unit at the JUH were examined for bisphosphonate-related osteonecrosis of the jaws (BRONJ). Diagnosis was made according to the guidelines of the American Association of Oral and Maxillofacial Surgeons (AAOMS) original position paper. RESULTS Of the 41 patients, four developed BRONJ, two in maxilla, one in mandible and one bimaxillary. Patients with BRONJ were older; mean age was 69.3 ±3.1 years compared to 62.8 ± 12.5 years (P = 0.022). Dental co-morbidities were more commonly present in patients with the disease (P = 0.038). Patients who developed BRONJ were on treatment for a longer duration of time; the mean duration of treatment was 23.5 ± 8.4 months compared to 11.9 ± 13.4 months (P = 0.10). CONCLUSIONS The results of this case series demonstrated that age and poor oral health status are significant risk factors of BRONJ for oncology patients on long-term frequent dosing schedule of i.v. bisphosphonates.Keywords
This publication has 19 references indexed in Scilit:
- American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 UpdateJournal of Oral and Maxillofacial Surgery, 2009
- Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cellsClinical Oral Investigations, 2009
- Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysisBlood, 2008
- Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control StudyJournal of Oral and Maxillofacial Surgery, 2008
- Bisphosphonate osteonecrosis of the jaws; an increasing problem for the dental practitionerBritish Dental Journal, 2007
- A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myelomaLeukemia, 2007
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Modified Fibonacci SearchJournal of Clinical Oncology, 2003
- Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogencontaining bisphosphonates on osteoclast precursorsBone, 2002
- Bisphosphonates: mechanisms of action.Journal of Clinical Investigation, 1996